AGP Picks
View all

Choroidal neovascularization market seen rising to $5.99 billion by 2030

18 hours ago
Choroidal neovascularization market seen rising to $5.99 billion by 2030
By AI, Created 18:45 UTC, Nov 18, 2026, AGP -

The choroidal neovascularization market is projected to grow from $4.18 billion in 2025 to $4.5 billion in 2026, with long-term demand driven by aging populations, more age-related macular degeneration and wider use of anti-VEGF therapies. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - Choroidal neovascularization can damage the retina and lead to distorted vision or vision loss. - Rising demand for earlier diagnosis and effective treatment is pushing the market toward steady growth through 2030. - The condition is closely tied to age-related macular degeneration, a major cause of irreversible vision loss in older adults.

What happened: - The Business Research Company published its Choroidal Neovascularization Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report values the market at $4.18 billion in 2025 and projects $4.5 billion in 2026. - The report forecasts the market will reach $5.99 billion by 2030. - The report covers regions including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company also offered a free sample of the market report and a full report.

The details: - The market’s projected growth from 2025 to 2026 implies a 7.7% compound annual growth rate. - The forecast period from 2026 to 2030 implies a 7.4% compound annual growth rate. - Growth drivers cited for the near term include rising cases of age-related macular degeneration, more diabetic eye disease, growth in ophthalmology clinics, better access to anti-angiogenic drugs and improved retinal diagnostic tools. - Longer-term growth is expected to come from an aging global population, earlier ophthalmic intervention, broader use of combination therapies, more investment in retinal disease research and personalized treatment strategies. - Key trends expected to shape the market include expanded use of anti-VEGF therapies, treat-and-extend protocols, stronger demand for early detection, better retinal imaging and more therapies focused on preserving vision. - Choroidal neovascularization forms abnormal blood vessels in the choroid that can extend into the retina and leak fluid or blood. - In 2025, the UHN Foundation said age-related macular degeneration was the leading cause of irreversible, significant vision loss in people over 50. - The UHN Foundation said more than 200 million people worldwide currently have age-related macular degeneration, with that number projected to rise to 288 million by 2040.

Between the lines: - The market story is being driven by a mix of demographic pressure and better treatment access. - Anti-VEGF drugs remain central because they target the abnormal vessel growth that defines wet AMD and related disease progression. - North America’s leading share suggests mature adoption of diagnostics and therapies, while Asia-Pacific’s faster growth points to expanding access and rising disease burden.

What's next: - The market’s next phase will likely be shaped by broader use of early screening, combination treatment approaches and personalized care. - More clinical and research investment could support new retinal therapies and imaging tools through the end of the decade. - The company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspot infographics and updated graphics and tables.

The bottom line: - The choroidal neovascularization market is expanding on the back of an aging population, rising AMD cases and continued innovation in retinal care.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

LATAM News Online

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

LATAM News Online

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.